Litcius/Paper detail

The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice

Xia Ren, Jiaying Xiong, Lingzhi Liang, Yin Chen, Guisen Zhang

2022Molecules14 citationsDOIOpen Access PDF

Abstract

Here, we explored the possible interaction between duloxetine and SEP-363856 (SEP-856) in depression-related reactions. The results showed that oral administration of duloxetine showed powerful antidepressant-like effects in both the forced swimming test (FST) and the suspension tail test (TST). SEP-856 orally administered alone also exerted an antidepressant-like effect in FST and TST, especially at doses of 0.3, 1, and 10 mg/kg. In addition, duloxetine (15 mg/kg) and SEP-856 (15 mg/kg) both showed antidepressant-like effects in the sucrose preference test (SPT). Most importantly, in the above experiments, compared with duloxetine alone, the simultaneous use of duloxetine and SEP-856 caused a more significant antidepressant-like effect. It is worth noting that doses of drug combination in FST and TST did not change the motor activities of mice in the open-field test (OFT). Thus, duloxetine and SEP-856 seem to play a synergistic role in regulating depression-related behaviors and might be beneficial for refractory depression.

Topics & Concepts

DuloxetineTail suspension testBehavioural despair testAntidepressantDuloxetine HydrochloridePharmacologyOpen fieldChemistryAgonistReboxetineInternal medicinePsychologyReceptorMedicineReuptake inhibitorHippocampusPathologyAlternative medicineTreatment of Major DepressionNeurotransmitter Receptor Influence on BehaviorReceptor Mechanisms and Signaling
The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice | Litcius